HAINS Mycobacterium Tuberculosis First Line Drug Resistance Profile Test
Comprehensive TB Drug Resistance Detection
The HAINS Mycobacterium Tuberculosis First Line Drug Resistance Profile Test represents a significant advancement in tuberculosis management and treatment optimization. This sophisticated molecular diagnostic test utilizes cutting-edge PCR and line probe assay technology to detect genetic mutations associated with drug resistance in Mycobacterium tuberculosis strains. As tuberculosis remains a major global health concern with increasing rates of drug-resistant strains, this test provides critical information that directly impacts treatment success and patient outcomes.
What This Revolutionary Test Detects
This comprehensive profile specifically identifies resistance patterns to essential first-line tuberculosis medications:
- Isoniazid Resistance: Detects mutations in katG and inhA genes
- Rifampin Resistance: Identifies mutations in rpoB gene region
- Ethambutol Resistance: Screens for embB gene mutations
- Pyrazinamide Resistance: Detects pncA gene alterations
Who Should Consider This Critical Test
This test is essential for several patient populations and clinical scenarios:
Primary Indications
- Patients with confirmed tuberculosis showing poor response to standard treatment
- Individuals with suspected multidrug-resistant TB (MDR-TB)
- Healthcare workers with occupational TB exposure
- Immigrants from high TB burden countries
- HIV-positive individuals with TB co-infection
- Patients with recurrent tuberculosis episodes
- Individuals with close contact to known drug-resistant TB cases
Clinical Symptoms Warranting Testing
- Persistent cough lasting more than 3 weeks
- Unexplained weight loss and night sweats
- Hemoptysis (coughing up blood)
- Chest pain and breathing difficulties
- Fever and fatigue that doesn’t resolve
- Treatment failure with first-line anti-TB drugs
Significant Benefits of Early Detection
Improved Treatment Outcomes
Early identification of drug resistance enables healthcare providers to:
- Select appropriate second-line medications promptly
- Avoid ineffective treatments that delay recovery
- Reduce the risk of developing extensively drug-resistant TB (XDR-TB)
- Shorten overall treatment duration
- Minimize medication side effects from ineffective drugs
Public Health Advantages
- Prevents transmission of drug-resistant strains
- Supports effective infection control measures
- Contributes to regional TB resistance surveillance
- Helps contain healthcare-associated outbreaks
Understanding Your Test Results
Interpretation Guidelines
Your test results will provide clear information about resistance patterns:
Sensitive Results
- No detected resistance mutations
- Standard first-line treatment likely to be effective
- Continue prescribed anti-TB regimen as directed
Resistant Results
- Specific resistance patterns identified
- Consultation with infectious disease specialist recommended
- Treatment modification required based on resistance profile
- Enhanced monitoring and longer treatment duration may be necessary
Indeterminate Results
- Repeat testing may be required
- Clinical correlation essential
- Alternative diagnostic methods may be considered
Test Pricing and Availability
| Test Description | Regular Price | Discount Price |
|---|---|---|
| HAINS Mycobacterium Tuberculosis First Line Drug Resistance Profile Test | $126 USD | $76 USD |
Turnaround Time and Sample Requirements
- Sample Collection: Tuesday or Friday by 11:00 AM
- Report Availability: Thursday or Monday
- Sample Type: 2 mL (1 mL minimum) Sputum, Bronchoalveolar Lavage, Pleural aspirates, CSF, Body fluid OR Cultured growth on appropriate media
- Shipping Instructions: Refrigerated transport in sterile screw-capped container within sealed plastic bag. DO NOT FREEZE
- Preparation: No special preparation required
Nationwide Accessibility
We have diagnostic centers conveniently located across the United States, serving major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, San Francisco, and many more. Our extensive network ensures that quality TB drug resistance testing is accessible to patients nationwide.
Take Control of Your TB Treatment Today
Don’t let uncertainty about drug resistance compromise your tuberculosis treatment. The HAINS Mycobacterium Tuberculosis First Line Drug Resistance Profile Test provides the critical information needed to ensure you receive the most effective treatment regimen. Early detection of resistance can significantly improve your recovery prospects and prevent the development of more resistant strains.
Ready to get tested? Call our dedicated healthcare line at +1(267) 388-9828 to schedule your appointment or speak with our medical professionals about your testing needs. We’re here to help you navigate your TB treatment with confidence and precision.
Our experienced team understands the urgency of tuberculosis diagnosis and treatment. We prioritize rapid processing and accurate results to support your healthcare provider in making timely treatment decisions. Trust General Genetics Corporation for reliable, advanced molecular diagnostics that make a difference in patient care.
